搜索优化
Rewards
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按相关度排序
按时间排序
1 天
Viatris 2023 Sustainability Report: Reducing Packaging Material
NORTHAMPTON, MA / ACCESSWIRE / October 10, 2024 / Viatris is continuously looking for ways to reduce the volume and types of ...
3 天
Viatris在日本广泛性焦虑障碍研究中报告EFFEXOR取得积极结果
在其他近期新闻中,Viatris Inc.在财务和运营表现方面取得了重大进展。公司最近报告了强劲的2024年第二季度业绩,总收入达到38亿美元,运营收入增长2%。调整后的息税折旧及摊销前利润(EBITDA)上升至12亿美元,调整后每股收益(EPS)报告为0.69美元。这些积极结果使Viatris将2024年新产品收入预测提高到5亿至6亿美元之间。
4 天
Novo Nordisk settles US patent fight with Viatris over Ozempic
Novo Nordisk and Viatris have agreed to resolve a patent dispute related to Novo's blockbuster weight-loss drugs Ozempic and ...
3 天
on MSN
Is Viatris Inc. (NASDAQ:VTRS) The Best NASDAQ Stock Under $20?
We recently made a list of 10 Best NASDAQ Stocks Under $20 to Buy. In this piece, we will look at where Viatris Inc.
腾讯网
4 天
诺和诺德就减肥药Ozempic和Wegovy专利纠纷与迈兰制药达成和解
诺和诺德与Viatris旗下迈兰制药在一份联合文件中表示,已同意解决与诺和诺德减肥药Ozempic和Wegovy相关的专利纠纷。此前诺和诺德已分别在法院起诉Viatris和其他公司侵犯专利,以阻止拟议的仿制药。诺和诺德发言人当地时间10月7日证实了和解协议。
3 天
Viatris: EFFEXOR Meets Primary And All Secondary Efficacy Endpoints In Japan - Quick Facts
Viatris (VTRS) reported positive top-line results of Phase 3 study in Japan evaluating the safety and efficacy of EFFEXOR in adults ...
4 天
on MSN
Novo Nordisk, Viatris settle patent dispute over Ozempic, Wegovy: report
Novo Nordisk (NVO) and Viatris (NASDAQ:VTRS) have reportedly reached an agreement in their dispute over U.S. patents ...
10 天
on MSN
Is Viatris Inc. (VTRS) the Best Stock Under $15 To Buy Now?
We recently compiled a list of 10 Best Stocks Under $15 To Buy Now. In this article, we will look at where Viatris Inc.
BioSpace
3 天
Novo, Viatris Settle Ozempic Patent Row
Alongside the settlement, Novo and Viatris have asked the U.S. Patent and Trademark Office to terminate its review of the ...
2 天
诺和诺德与迈兰达成 Ozempic (司
根据美国专利局专利审判和上诉委员会周三做出的决定,在美国针对诺和诺德的专利案将被允许继续审理。 仿制药生产商 Viatris 对诺和诺德的 GLP-1 分子 Semaglutide 的三项专利提出了质疑,因为该公司认为这些专利实际上是基于糖尿病药物利拉鲁肽的,因此应予以撤销。 本周早些时候,仲裁庭拒绝对其中两项挑战进行“当事人审查”,但周三决定继续审理第三项挑战的案件。 “当事人复审”是美国专利制 ...
3 天
Viatris Announces Positive Top-line Results from Phase 3 Study of EFFEXOR® in Japanese ...
Viatris Announces Positive Top-line Results from Phase 3 Study of EFFEXOR® in Japanese Adults with Generalized Anxiety ...
CSR Wire
2 天
Viatris Named to Forbes' Annual List of the World's Best Employers for the Fourth Year in a Row
Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that it has been named to Forbes' list of World's Best Employers 2024.
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈